A 2 × 2 factorial randomized controlled trial of a commercial M. bovis (CMB) vaccine and a conditionally licensed M. bovoculi vaccine (CLMB) to prevent IBK

Abstract

Infectious bovine keratoconjunctivitis (IBK) is an economically important disease of beef cattle. Currently, there is little pub­lic evidence from randomized controlled trials that the differ­ent vaccines and vaccination regimes available to prevent IBK in cattle are effective, including autogenous and commercial vaccines directed at Moraxella bovis or Moraxella bovoculi. The combined use of a commercial M. bovis (CMB) vaccine and a conditionally licensed M. bovoculi vaccine (CLMB) has yet to be publicly evaluated.